drugset / Trial / NCT07522996

Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA

NCT07522996

RandomizedParallel-groupOpen-labelTreatment

Summary

This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine alone in the treatment of TD-NSAA.

Timeline

Start
2026-06
Primary completion
2028-12
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 3 mg/kg
Subject Cyclosporine Peptide 5 mg/kg
Subject Enarodustat Small molecule 8 mg

Indications